Aspirin's effect on platelet inhibition in migraineurs

Headache

Volumn 52, Issue 8, 2012, Pages 1207-1218

  Jesurum, Jill T ^a   Fuller, Cindy J ^a   Murinova, Natalia ^b   Truva, Colleen M ^a   Lucas, Sylvia M ^b  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

aspirin; aspirin resistance; migraine; platelet; platelet reactivity; stroke

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH ON ASPIRIN PLATELET REACTIVITY; HUMAN; MALE; MEDICAL HISTORY; MELENA; MIGRAINE; MIGRAINE WITH AURA; PATIENT COMPLIANCE; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84865865596     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02143.x     Document Type: Article

References (70)

1. Bigal ME, Kurth T, Santanello N, et al,. Migraine and cardiovascular disease. A population-based study. Neurology. 2010; 74: 628-635.
2. Kurth T, Schurks M, Logroscino G, Buring JE,. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009; 73: 581-588.
3. Caminero AB, Sanchez Del Rio Gonzalez M,. Migraine as a cerebrovascular risk factor. Neurologia. 2012; 27: 103-111.
4. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T,. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ. 2009; 339: b3914.
5. Scher AI, Gudmundsson LS, Sigurdsson S, et al,. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009; 301: 2563-2570.
6. Martinez-Sanchez P, Fuentes B, Fernandez-Dominguez J, et al,. Young women have poorer outcomes than men after stroke. Cerebrovasc Dis. 2011; 31: 455-463.
7. Zeller JA, Frahm K, Baron R, Stingele R, Deuschl G,. Platelet-leukocyte interaction and platelet activation in migraine: A link to ischemic stroke? J Neurol Neurosurg Psychiatry. 2004; 75: 984-987.
8. Angiolillo DJ, Ueno M, Goto S,. Basic principles of platelet biology and clinical implications. Circ J. 2010; 74: 597-607.
9. Lowenberg EC, Meijers JC, Levi M,. Platelet-vessel wall interaction in health and disease. Neth J Med. 2010; 68: 242-251.
10. Pabinger I, Ay C,. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol. 2009; 29: 332-336.
11. del Zoppo GJ,. The role of platelets in ischemic stroke. Neurology. 1998; 51: S9-14.
12. Nozari A, Dilekoz E, Sukhotinsky I, et al,. Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol. 2010; 67: 221-229.
13. Sarchielli P, Alberti A, Coppola F, et al,. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia. 2004; 24: 623-630.
14. Kitano A, Shimomura T, Takeshima T, Takahashi K,. Increased 11-dehydrothromboxane B2 in migraine: Platelet hyperfunction in patients with migraine during headache-free period. Headache. 1994; 34: 515-518.
15. Htun P, Fateh-Moghadam S, Tomandl B, et al,. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke. 2006; 37: 2283-2287.
16. Antman EM, DeMets D, Loscalzo J,. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005; 112: 759-770.
17. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. Steering committee of the physicians' health study research group. N Engl J Med. 1989; 321: 129-135.
18. Ridker PM, Cook NR, Lee IM, et al,. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304.
19. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150: 396-404.
20. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV,. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med. 2007; 167: 1593-1599.
21. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM,. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost. 2010; 8: 2140-2148.
22. Gurbel PA, Kereiakes DJ, Atar D, Serebruany VL,. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. Scand Cardiovasc J. 2000; 34: 53-58.
23. Gum PA, Kottke-Marchant K, Poggio ED, et al,. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88: 230-235.
24. Wang JC, Aucoin-Barry D, Manuelian D, et al,. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol. 2003; 92: 1492-1494.
25. Eikelboom JW, Hankey GJ, Thom J, et al,. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Determinants and effect on cardiovascular risk. Circulation. 2008; 118: 1705-1712.
26. Coleman JL, Wang JC, Simon DI,. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA System. Point Care. 2004; 3: 77-82.
27. Andersen K, Hurlen M, Arnesen H, Seljeflot I,. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002; 108: 37-42.
28. Gurbel PA, Bliden KP, DiChiara J, et al,. Evaluation of dose-related effects of aspirin on platelet function: Results from the aspirin-induced platelet effect (ASPECT) study. Circulation. 2007; 115: 3156-3164.
29. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR,. Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ. 2008; 336: 195-198.
30. Kurth T, Diener HC, Buring JE,. Migraine and cardiovascular disease in women and the role of aspirin: Subgroup analyses in the women's health study. Cephalalgia. 2011; 31: 1106-1115.
31. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
32. Kosinski M, Bayliss MS, Bjorner JB, et al,. A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res. 2003; 12: 963-974.
33. Lipton RB, Stewart WF, Sawyer J, Edmeads JG,. Clinical utility of an instrument assessing migraine disability: The migraine disability assessment (MIDAS) questionnaire. Headache. 2001; 41: 854-861.
34. Olesen J, Bousser MG, Diener HC, et al,. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
35. Silberstein SD, Olesen J, Bousser MG, et al,. The international classification of headache disorders, 2nd edition (ICHD-II)-revision of criteria for 8.2 medication-overuse headache. Cephalalgia. 2005; 25: 460-465.
36. Coleman JL, Alberts MJ,. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol. 2006; 98: 838-841.
37. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ,. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006; 37: 2153-2158.
38. Campbell CL, Smyth S, Montalescot G, Steinhubl SR,. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA. 2007; 297: 2018-2024.
39. Accumetrics VerifyNow Assay Insert. Accumetrics: San Diego, CA; 2009.
40. Nielsen HL, Kristensen SD, Thygesen SS, et al,. Aspirin response evaluated by the VerifyNow⢠Aspirin System and Light Transmission Aggregometry. Thromb Res. 2008; 123: 267-273.
41. DiChiara J, Bliden KP, Tantry US, et al,. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets. 2007; 18: 414-423.
42. Golanski J, Nocun M, Rozalski M, Drygas W, Watala C,. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis. 2004; 15: 187-195.
43. Karon BS, Wockenfus A, Scott R, et al,. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem. 2008; 54: 1060-1065.
44. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF,. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
45. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G,. Potential source of cerebral embolism in migraine with aura: A transcranial doppler study. Neurology. 1999; 52: 1622-1625.
46. Domitrz I, Mieszkowski J, Kwiecinski H,. [The prevalence of patent foramen ovale in patients with migraine]. Neurol Neurochir Pol. 2004; 38: 89-92.
47. Henry P, Vermillet A, Boval B, et al,. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2011; 105: 336-344.
48. Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG,. Response to aspirin in healthy individuals. Cross-comparison of Light Transmission Aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost. 2009; 102: 404-411.
49. Michelson AD,. Methods for the measurement of platelet function. Am J Cardiol. 2009; 103: 20A-26A.
50. Cattaneo M,. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost. 2007; 5 (Suppl. 1): 230-237.
51. Grove EL, Hvas AM, Johnsen HL, et al,. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010; 103: 1245-1253.
52. Frelinger AL 3rd, Furman MI, Linden MD, et al,. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation. 2006; 113: 2888-2896.
53. Qayyum R, Becker DM, Yanek LR, et al,. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008; 101: 1359-1363.
54. Dorsch MP, Lee JS, Lynch DR, et al,. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007; 41: 737-741.
55. Kurth T, Gaziano JM, Cook NR, et al,. Migraine and risk of cardiovascular disease in men. Arch Intern Med. 2007; 167: 795-801.
56. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE,. Migraine and risk of cardiovascular disease in women. JAMA. 2006; 296: 283-291.
57. Caprini JA, Glase CJ, Anderson CB, Hathaway K,. Laboratory markers in the diagnosis of venous thromboembolism. Circulation. 2004; 109: I-4-I-8.
58. Tietjen GE, Al-Qasmi MM, Athanas K, Utley C, Herial NA,. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res. 2007; 119: 217-222.
59. Hering-Hanit R, Friedman Z, Schlesinger I, Ellis M,. Evidence for activation of the coagulation system in migraine with aura. Cephalalgia. 2001; 21: 137-139.
60. Pilarska E, Lemka M, Bakowska A,. Prothrombotic risk factors in ischemic stroke and migraine in children. Acta Neurol Scand. 2006; 114: 13-16.
61. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA,. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009; 40: 2977-2982.
62. Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM,. Vascular risk factors, endothelial function, and carotid thickness in patients with migraine: Relationship to atherosclerosis. J Stroke Cerebrovasc Dis. 2010; 19: 92-103.
63. Chen WH, Cheng X, Lee PY, et al,. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007; 120: 631-635.
64. Frelinger AL, Li Y, Linden MD, et al,. Aspirin "resistance": Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008; 6: 2035-2044.
65. Guthikonda S, Alviar CL, Vaduganathan M, et al,. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008; 52: 743-749.
66. Bordeaux BC, Qayyum R, Yanek LR, et al,. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol. 2010; 13: 56-62.
67. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H,. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003; 27: 907-911.
68. Mirkhel A, Peyster E, Sundeen J, et al,. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006; 98: 577-579.
69. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J,. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004; 35: 175-178.
70. DiChiara J, Bliden KP, Tantry US, et al,. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007; 56: 3014-3019.